|本期目录/Table of Contents|

[1]王勇 综述,牛远杰 审校.DNA错配修复基因在CRPC精准治疗的临床应用进展[J].天津医科大学学报,2020,26(05):490-493.
点击复制

DNA错配修复基因在CRPC精准治疗的临床应用进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
26卷
期数:
2020年05期
页码:
490-493
栏目:
综述
出版日期:
2020-09-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2020)05-0490-04
作者:
王勇 综述; 牛远杰 审校
（天津医科大学第二医院泌尿外科，天津市泌尿外科研究所，天津 300211）
Author(s):
-
关键词:
DNA错配修复基因; 去势抵抗性前列腺癌; 精准治疗
Keywords:
-
分类号:
R737.25
DOI:
-
文献标志码:
A
摘要:
前列腺癌是一种常见的男性泌尿生殖系统恶性肿瘤，严重威胁男性健康。前列腺癌经过初期的雄激素剥夺治疗后会进展为去势抵抗性前列腺癌。去势抵抗性前列腺癌的异质性也决定了其治疗的 复杂性。随着第二代测序技术的发展和应用，去势抵抗性前列腺癌的治疗也进入了精准时代。DNA错配修复基因在去势抵抗性前列腺癌的发病中起重要作用。以多聚二磷酸腺苷核糖聚合酶（PARP）抑制剂 、免疫检查点抑制剂为基础的精准治疗为存在DNA错配修复基因缺陷的去势抵抗性前列腺癌患者的治疗带来了新的希望。
Abstract:
-

参考文献/References:

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394
[2] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115
[3] James N D, Spears M R, Clarke N W, et al. Survival with newly diagnosed metastatic prostate cancer in the“Docetaxel Era”:data from 917 patients in the control arm of the STAMPEDE trial(MRC PR08,CRUK/06/019)[J]. Eur Urol, 2015, 67(6):1028
[4] 王准,温思萌,朱识淼,等. 去势抵抗性前列腺癌的病因学分型研究和临床精准医疗实践探索[J]. 临床外科杂志, 2017, 25(7): 551
[5] Hovelson D H, Tomlins S. The role of next-generation sequencing in castration-resistant prostate cancer treatment[J].Cancer J, 2016, 22(5): 357
[6] 中国临床肿瘤学会肿瘤标志物专家委员会. 中国肿瘤驱动基因分析联盟.二代测序技术在肿瘤精准医学诊断中的应用专家共识[J].中华医学杂志, 2018, 98(26):2057
[7] Beltran H, Yelensky R, Frampton G M, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity[J].Eur Urol, 2013, 63(5):920
[8] Robinson D, Van Allen E M, Wu Y M, et al. Integrative clinical genomics of advanced prostate cancer[J]. Cell, 2015, 161(5):1215
[9] Pitchard C C, Mateo J, Wa1sh M F, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer[J]. N Engl J Med, 2016, 375(5): 443
[10] Wei Y, Wu J, Gu W, et al. Germline DNA repair gene mutation landscape in Chinese prostate cancer patients[J].Eur Urol,2019, 76(3):280
[11] Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of noda1 involvement, distant metastasis, and poor survival outcomes in prostate cancer[J]. J Clin Oncol, 2013, 31(14):1748
[12] Mateo J, Boysen G, Barbieri C E, et al. DNA repair in prostate cancer: biology and clinical implications[J]. Eur Urol, 2017, 71(3):417
[13] Krishnakumar R, Kraus W L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets[J]. Mol Cell, 2010, 39(1):8
[14] Rouleau M, Patel A, Hendzel M J, et al. PARP inhibition: PARP1 and beyond[J]. Nat Rev Cancer, 2010, 10(4):293
[15] Schreiber V, Dantzer F, Ame J C, et al. Poly(ADP-ribose):novel functions for an old molecule[J]. Nat Rev Mol Cell Biol, 2006, 7(7):517
[16] Goodall J, Mateo J, Yuan W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition[J]. Cancer Discov, 2017, 7(9):1006
[17] Mateo J, Carreira S, Sandhu S, et al. DNA-Repair defects and olaparib in metastatic prostate cancer[J]. N Engl J Med, 2015, 373(18):1697
[18] Smith M, Sandhu S, Kelly W, et al. Pre-specified interim analysis of GALAHAD: a Phase 2 study of niraparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects. ESMO 2019 Congress[C]. Annals of Oncology, 2019, 30 (Suppl 5): v851
[19] Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer:a randomised,double-blind, placebo-controlled,phase 2 trial[J]. Lancet Oncol, 2018, 19(7):975
[20] Ni J M, Ni A P. Landscape of PD-1/PD-L1 regulation and targeted immunotherapy[J].Chin Med Sci J, 2018, 33(3):174
[21] Zhang J, Dang F, Ren J, et al. Biochemical aspects of PD-L1 regulation in cancer immunotherapy[J].Trends Biochem Sci, 2018, 43(12):1014
[22] Weng Y M, Peng M, Hu M X, et al. Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis[J]. Onco Targets Ther, 2018, 11:7529
[23] Sfanos K S, Bruno T C, Meeker A K, et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+[J]. Prostate, 2009, 69(15): 1694
[24] Massari F, Ciccarese C, Calio A, et al. Magnitude of PD-1,PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis[J].Target Oncol,2016, 11(3):345
[25] Graff J N, Alumkal J J, Drake C G, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer[J]. Oncotarget, 2016, 7(33):52810
[26] Abida W, Cheng M L, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade[J]. JAMA Oncol, 2019, 5(4): 471
[27] Rexer H, Graefen M, Merseburger A, et al. Phase Ⅱstudy of pembrolizumab(MK-3475) in patients with metastatic castration-resistant prostate cancer(KEYNOTE-199)-study AP 93/16 of the AUO[J]. Urologe A, 2017, 56(11): 1471
[28] Hansen A R, Massard C, Ott P A, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study[J].Ann Oncol, 2018, 29(8):1807
[29] Yeku O, Slovin S F. Immune therapy for prostate cancer[J].Cancer J,2016, 22(5): 334
[30] Antonarakis E S, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer[J]. N Engl J Med, 2014, 371(11):1028
[31] Nakazawa M, Antonarakis E S,Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone[J]. Horm Cancer,2014, 5(5): 265
[32] Beltran H, Prandi D, Mosquera J M, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer[J]. Nat Med, 2016, 22(3): 298
[33] Beltran H, Rickman D S, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets[J]. Cancer Discov, 2011, 1(6): 487
[34] Armenia J, Wankowicz S, Liu D, et al. The long tail of oncogenic drivers in prostate cancer[J]. Nat Genet, 2018, 50(5): 645
[35] Zhao T, Liao B, Yao J, et al. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?[J]. Prostate, 2015, 75(3): 225

相似文献/References:

备注/Memo

备注/Memo:
基金项目 国家自然科学基金面上项目资助（81872078）；天津市自然科学基金面上项目资助（18JCYBJC26700）；天津医科大学第二医院临床研究项目资助（ChiCTR1900024895）
作者简介 王勇（1981-），男，副主任医师、副教授，博士，研究方向：去势抵抗性前列腺癌的分型治疗；
通信作者：牛远杰，E-mail:niuyuanjie9317@163.com。
更新日期/Last Update: 2020-09-18